UCB this week announced an agreement to enter into a world-wide, exclusive license agreement with Roche for the global development and commercialization of UCB0107 in Alzheimer’s Disease (AD). In return, UCB will receive an initial upfront payment of $120 million. UCB will fund and perform a proof-of-concept study in AD and, upon availability of the results of that study, Genentech has the right to progress with the development or return full rights back to UCB. After Genentech’s decision to proceed with further clinical development, UCB will be eligible to receive further potential cost reimbursement, development and sales milestone payments. Learn More